This is a single centre, double-blind, randomised, parallel group, placebo controlled study
to assess the safety, tolerability and pharmacokinetics of AZD1386 when given as multiple
doses to 32 (24 healthy young and 8 healthy elderly) Japanese subjects. For young healthy
subjects (aged ≥20 to ≤45 inclusive) 3 consecutive multiple ascending dose panels are
planned. For elderly healthy subjects (aged ≥65 to≤80 inclusive) 1 multiple dose panel is
planned.